SEC Filing Analysis: MAIA Biotechnology, Inc. (MAIA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Director Steven M. Chaouki received a routine grant of 32,774 stock options with an exercise price of $1.18 per share.
• Market Impact: Neutral, as the transaction represents standard board compensation with negligible dilution.

Company Information

Field	Value
Company	MAIA Biotechnology, Inc.
Ticker Symbol	MAIA
CIK	0001878313
Industry	Pharmaceutical Preparations [2834]

Insider Information

Field	Value
Name	CHAOUKI STEVEN M
CIK	0001776865
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-09-30
Transaction Code	A (Award/Grant)
Security Type	Stock Options (right to buy)
Shares Involved	32,774
Price Per Share	$0.00 (Exercise price: $1.18)
Total Value	$0.00
Shares Owned After	32,774
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0.00
% of Market Cap	0.00%
Shares Transacted	32,774
% of Shares Outstanding	0.05%
Post-Transaction Ownership	32,774 options (0.05% of outstanding upon exercise)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For MAIA's market capitalization of approximately $70 million, an option award underlying ~$38,673 in exercise value is immaterial to corporate valuation.
• Ownership Concentration: Insider ownership from this award accounts for just 0.05% of total common shares outstanding.
• Dilution Impact: The grant results in a negligible potential dilution of 0.05% upon exercise.
• Transaction Significance: Routine annual/quarterly board compensation with minimal economic impact.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Routine equity grant under the 2021 Equity Incentive Plan with negligible dilution and no open-market activity.

Volume & Sentiment

• Expected Volume Impact: None expected.
• Sentiment Indicator: Neutral

Additional Context

Transaction Notes

• Timing: Effective September 30, 2026; filed on October 2, 2026.
• Special Circumstances: Options were granted pursuant to the company's 2021 Equity Incentive Plan, vest 100% on the date of grant, and expire on September 30, 2036.